OmniAb, Inc.
Moat Score — OmniAb, Inc.
Total Moat Score
13 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 4 / 5 | OmniAb holds patent-protected, differentiated transgenic animal platforms across rat, mouse, chicken, and cow hosts (including the distinctive cow-derived OmniTaur ultralong CDRH3 antibodies), a technical and IP breadth that would take years and significant capital for a new entrant to replicate. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | OmniAb is a specialized R&D technology licensor, not a low-cost producer; it competes on platform differentiation and partner relationships rather than any cost structure advantage. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 2 / 5 | Technology access fees, milestones, and royalty rates (low- to mid-single digits) are negotiated per partner against a real set of alternatives (AbCellera, in-house platforms at Regeneron, traditional CROs), giving OmniAb some but not dominant pricing leverage. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 1 / 5 | Having more partners and programs does not directly make the discovery platforms better for other partners in a disclosed way; this is a licensing business without a clear multi-sided network effect. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 3 / 5 | Once a partner has advanced a specific OmniAb-derived antibody sequence into IND-enabling or clinical studies, switching to a different discovery platform for that program is effectively impossible without restarting development, embedding real program-level lock-in even though switching for a *future*, not-yet-started program is easy. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 2 / 5 | The market for licensed, multi-species antibody discovery platforms is a real niche that supports a handful of credible players (OmniAb, AbCellera, Harbour BioMed) rather than dozens, but it is not so narrow that new, well-funded entrants or expanded in-house capability at large pharma couldn't erode it. |